Engineeringthe Next
Standard of Care
Triple Helix Science is an institutional-grade biotechnology company built for governments, institutions, and enterprise partnerships.

A NEW ERA AGAINST CANCER, DEMENTIA, AND AGING WITH GENES | 076 DR. PATRICK E. SEWELL, MD
Our Divisions
Core Operating Divisions of Triple Helix Science
Sovereign Partnerships
Partnering with sovereign governments, hospitals, medical schools, and research institutes for manufacturing & clinical translation.
Triple Helix Medicine
Clinical partner delivering 17+ medical specialty divisions, advanced gene/cell therapies, and physician referral pathways.
Triple Helix Corporate
Group operations — manufacturing across four regions, regulatory and quality affairs, regional subsidiaries, and the vector platforms shared by every clinical division.
Triple Helix Veterinary
Bringing human gene and cellular medical science to companion animals across Mexico City, Dubai, and Abu Dhabi.
Triple Helix Lifestyle
Physician-supervised gene and cell programs for recovery, resilience, and sustained physical function.
Triple Helix Compassion
Our sister charity BioHelix NP providing life-saving gene and cell therapies to patients in need globally.
Environmental Science
Gene-therapy heat-resistant coral, ocean acidification mitigation, and solar-powered fresh water chemistry.
Science Platforms & Global Footprint
Proprietary platforms, gmp-grade manufacturing, and sovereign infrastructure

Triple Helix Medicine: 17 Medical Specialty Divisions
Comprehensive translational care across dedicated clinical departments
RESEARCH & PUBLICATIONS
Latest Research
Recent peer-reviewed work by Dr. Patrick E. Sewell, MD on gene therapy, immunosenescence and the biology of aging.
Treating a systemic disease as a local one: failure points of current pancreatic cancer management and a multimodal, biology-guided framework for redesign
Frontiers in Oncology
Pancreatic ductal adenocarcinoma remains among the most lethal solid tumors, with 5-year survival near 13% despite decades of incremental change, and current management continues to be organized around anatomic resectability and a chemotherapy backbone applied largely without regard to tumor biology. This article advances the thesis that the dominant paradigm underperforms because it treats a systemic, molecularly convergent, multi-compartment disease as though it were a local one.
Patrick E. Sewell
Depleted before the dose: the mitochondrial vulnerability threshold hypothesis for fluoroquinolone-associated multisystem toxicity
Frontiers in Pharmacology
Fluoroquinolone (FQ) antibiotics have an established capacity for mitochondrial injury, yet only a subset of exposed patients develop severe or persistent toxicity. We propose the Mitochondrial Vulnerability Threshold (MVT) hypothesis: that whether a standard therapeutic FQ dose produces clinically significant toxicity may depend substantially on the patient’s pre-existing mitochondrial reserve capacity rather than on fixed pharmacological properties alone.
Patrick E. Sewell, Christopher J. Jensen
Affected by fluoroquinolone toxicity? Dr. Sewell can advise on treatment. Contact us to inquire, and we can send our supplement and recovery protocol sheet on request. Contact us
Hyaluronidase-enhanced delivery in gene therapy and regenerative medicine for improved vector, cell, and cargo access
Frontiers in Drug Delivery
Efficient delivery of gene therapy vectors and regenerative cargo to the central nervous system (CNS) is limited by the hyaluronic acid (HA)-rich extracellular matrix (ECM). Hyaluronidase enzymes transiently depolymerize HA, reducing tissue viscosity and increasing interstitial permeability through a well-defined, reversible mechanism. This narrative review synthesizes the mechanistic basis, evidence tiers, dosing and technique protocols, safety considerations, and translational knowledge gaps for hyaluronidase as a CNS delivery adjunct.
Patrick E. Sewell, Christopher Jensen

Connect with Triple Helix Science
Patient consultation requests, physician referral with secure record upload, and sovereign institutional partnership inquiries.












